Tango Therapeutics, Inc. (TNGX) FY2025 10-K Annual Report
Tango Therapeutics, Inc. (TNGX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 5, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Tango Therapeutics, Inc. FY2025 10-K Analysis
Risk Factors
- • Regulatory risk: FDA clinical trial approvals and safety profiling of PRMT5 inhibitors vopimetostat and TNG456 ongoing with multiple Phase 1/2 trials active in 2026
- • Macroeconomic exposure: Cash runway of $343.1M as of Dec 31, 2025 expected to fund operations only into 2028, requiring substantial additional capital raises
Tango Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$62M
▲ +48.3% YoY
Net Income
-$102M
▲ +22.0% YoY
Operating Margin
-178.4%
▲ +16769bp YoY
Net Margin
-162.9%
▲ +14688bp YoY
ROE
-29.3%
▲ +3596bp YoY
Total Assets
$399M
▲ +26.0% YoY
EPS (Diluted)
$-0.87
▲ +26.9% YoY
Operating Cash Flow
-$139M
▼ -5.6% YoY
Source: XBRL data from Tango Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tango Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.